What challenges did HSO face before AI implementation?

Sluggish drug development cycles hindered by manual clinical and regulatory processes. Operational inefficiencies in managing trial, molecular, and supply chain data. Complex compliance requirements (cGMP, FDA, CFR) demanded robust data traceability. Fragmented data systems across global research and manufacturing partners.

Source

MicrosoftProductionEvidence: Low40/100

HSO enables AI-powered process optimization for pharmaceutical R&D and compliance

Use case typeClinical documentationUpdated Jun 13, 2026

HSO, a global consulting and technology firm, has implemented advanced Microsoft technologies to support innovation, process automation, and regulatory compliance for pharmaceutical companies. By deploying Microsoft Copilot, Microsoft Fabric, Azure AI, and Gen AI, HSO's solutions automate key aspects of drug development and clinical trials, such as data management, adverse event reporting, patient engagement, and FDA submissions. HSO also partners with Merit Solutions for further integration and support. The solution includes analytics-driven product launch strategies and predictive supply chain insights. This digital transformation improves R&D productivity, enables faster time-to-market for products, efficiently manages molecular and clinical data, and ensures quality and compliance in life sciences operations.

Organization: HSO
Industry: Pharma
Location: United Kingdom

Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks

Customer: HSO
Provider: Microsoft
Maturity: Production
Linked source: hso.com

Operational inefficiencies in managing trial, molecular, and supply chain data

Customer identity supportedSource describes one deploymentMaturity supported

Primary read

Use case focus

Showing 2 of 2

1Automated clinical trial and adverse event data management
2AI-powered FDA submission and compliance automation

Deployed Microsoft Copilot and Microsoft Fabric for proof-of-concept trials.
Automated clinical trial compilation and adverse event reporting using AI and Fabric.
Enabled predictive patient support and FDA submissions automation via Copilot.
Integrated research and supply chain data with scalable, multi-cloud architecture.

Technologies

Microsoft Copilot Microsoft Fabric Azure AI

Improved R&D and trial productivity, lowering time-to-market for new drugs.

Architecture

Utilizes Microsoft Fabric to centralize and manage R&D and supply chain data from multiple sources. AI-driven automation (via Copilot) is layered to automate trial data compilation, adverse event tracking, and submission processes. Integration across cloud platforms (primarily Microsoft) ensures end-to-end compliance and analytics for drug development, patient care, and business partners.

Sources & evidence1

Evidence: Low40/100Evidence strength